Contract research organizations such as Icon (ICLR) are on a fast-growth track, thanks to rising drug development costs. The Ireland-based company provides drug development and clinical testing services to the pharmaceutical, biotech and medical-device industries. Icon has steadily grown via buyouts, acquiring at least one company each year for the past nine years, according to its website.